Send to

Choose Destination
See comment in PubMed Commons below
Front Pharmacol. 2011 Oct 24;2:61. doi: 10.3389/fphar.2011.00061. eCollection 2011.

Emerging therapies for acute coronary syndromes.

Author information

Cardiovascular Division, Hospital of the University of Pennsylvania Philadelphia, PA, USA.


In the majority of cases acute coronary syndromes (ACS) are caused by activation and aggregation of platelets and subsequent thrombus formation leading to a decrease in coronary artery blood flow. Recent focus on the treatment of ACS has centered on reducing the response of platelets to vascular injury as well as inhibiting fibrin deposition. Novel therapies include more effective P2Y12 receptor blockers thereby reducing inter-individual variability, targeting the platelet thrombin receptor (protease activated receptor 1) as well as directly inhibiting factor Xa or thrombin activity. In this review we discuss the clinical data evaluating the effectiveness of these various new ACS treatment options.


bivalirudin; dabigatran; fondaparinux; prasugrel; ticagrelor; vorapaxar

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Frontiers Media SA Icon for PubMed Central
    Loading ...
    Support Center